Virological and Immunological Impact of Tuberculosis on Human Immunodeficiency Virus Type 1 Disease

Journal of Infectious Diseases

Volumn 188, Issue 8, 2003, Pages 1146-1155

  Toossi, Zahra ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; ISONIAZID; PENTOXIFYLLINE; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BINDING SITE; CHRONIC DISEASE; COMORBIDITY; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE TRANSMISSION; DRUG POTENCY; GENETIC HETEROGENEITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; INHIBITION KINETICS; MEDICAL RESEARCH; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RECEPTOR BINDING; TUBERCULOSIS; VIROGENESIS; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HIV INFECTIONS; HIV-1; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VIRUS REPLICATION;

EID: 0242301613     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378676     Document Type: Article

References (94)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-86.
2. Selwyn PA, Hartel D, Wasserman W, Drucker E. Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am J Public Health 1989; 79:1358-62.
3. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992; 326:231-5.
4. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72:213-20.
5. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993; 96:1-11.
6. World Health Organization (WHO). WHO report 2001: global tuberculosis control. Available at: http://www.who.int/gtb/publications/ globrep02/ downloadpage.html.
7. Lucas S, Nelson AM. Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Bloom BR, ed. Tuberculosis: pathogenesis, protection, and control. Washington, DC: American Society for Microbiology Press, 1994:503-13.
8. Mayanja-Kizza H, Wajja A, Wu M, et al. Activation of β-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2001; 183:1801-4.
9. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001; 123:233-8.
10. Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14:1219-28.
11. Lado Lado FL, Barrio Gomez E, Carballo Arceo E, Cabarcos Ortiz de Barron A. Clinical presentation of tuberculosis and the degree of immunodeficiency in patients with HIV infection. Scand J Infect Dis 1999; 31:387-91.
12. Gilks CF, Brindle RJ, Otieno LS, et al. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. AIDS 1990; 4:981-5.
13. Nambuya A, Sewankambo N, Mugerwa J, Goodgame R, Lucas S. Tuberculous lymphadenitis associated with human immunodeficiency virus (HIV) in Uganda. J Clin Pathol 1988; 41:93-6.
14. Ackah AN, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995; 345:607-10.
15. Eriki PP, Okwera A, Aisu T, Morrissey AB, Ellner JJ, Daniel TM. The influence of human immunodeficiency virus infection on tuberculosis in Kampala, Uganda. Am Rev Respir Dis 1991; 143:185-7.
16. Johnson JL, Okwera A, Nsubuga P, et al. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis 2000; 4: 1032-40.
17. Kenyon TA, Creek T, Laserson K, et al. Risk factors for transmission of Mycobacterium tuberculosis from HIV-infected tuberculosis patients, Botswana. Int J Tuberc Lung Dis 2002; 6:843-50.
18. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342:268-72.
19. Fitzgerald DW, Severe P, Joseph P, et al. No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial. J Acquir Immune Defic Syndr 2001; 28:305-7.
20. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-47.
21. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beim Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 2000; 283:1445-50.
22. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 1998; 47(RR-20):1-58.
23. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129-35.
24. Del Amo J, Petruckevitch A, Phillips AN, et al. Risk factors for tuberculosis in patients with AIDS in London: a case-control study. Int J Tuberc Lung Dis 1999; 3:12-7.
25. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157:1271-8.
26. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801-8.
27. Shaunak S, Veryard C, Javan C. Severe Pneumocystis carinii pneumonia increases the infectious titre of HIV-1 in blood and can promote the expansion of viral chemokine co-receptor tropism. J Infect 2001; 43:3-6.
28. Koziel H, Kim S, Reardon C, et al. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1999; 160:2048-55.
29. Ostrowski MA, Krakauer DC, Li Y, et al. Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol 1998; 72:7772-84.
30. Vanham G, Edmonds K, Qing L, et al. Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clin Exp Immunol 1996; 103:30-4.
31. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997; 155:996-1003.
32. Toossi Z, Johnson JL, Kanost RA, et al. Increased Replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr 2001; 28:1-8.
33. Frye MD, Pozsik CJ, Sahn SA. Tuberculous pleurisy is more common in AIDS than in non-AIDS patients with tuberculosis. Chest 1997; 112: 393-7.
34. Richter C, Perenboom R, Mtoni I, et al. Clinical features of HIV-seropositive and HIV-seronegative patients with tuberculous pleural effusion in Dar es Salaam, Tanzania. Chest 1994; 106:1471-5.
35. Collins KR, Mayanja-Kizza H, Sullivan BA, Quinones-Mateu ME, Toossi Z, Arts EJ. Greater diversity of HIV-1 quasispecies in HIV-infected individuals with active tuberculosis. J Acquir Immune Defic Syndr 2000; 24:408-17.
36. Collins KR, Quinones-Mateu ME, Wu M, et al. Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol 2002; 76:1697-706.
37. Garrait V, Cadranel J, Esvant H, et al. Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J Immunol 1997; 159:2824-30.
38. Toossi Z. Cytokine circuits in tuberculosis. Infect Agents Dis 1996; 5: 98-107.
39. Schutze S, Machleidt T, Kronke M. Mechanisms of tumor necrosis factor action. Semin Oncol 1992; 19:16-24.
40. Means TK, Jones BW, Schromm AB, et al. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol 2001; 166:4074-82.
41. Hirsch CS, Ellner JJ, Russell, Rich EA. Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol 1994; 152:743-53.
42. Aung H, Toossi Z, Wisnieski JJ, et al. Induction of monocyte expression of tumor necrosis factor alpha by the 30-kD alpha antigen of Mycobacterium tuberculosis and synergism with fibronectin. J Clin Invest 1996; 98:1261-8.
43. Dahl KE, Shiratsuchi H, Hamilton BD, Ellner JJ, Toossi Z. Selective induction of transforming growth factor beta in human monocytes by lipoarabinomannan of Mycobacterium tuberculosis. Infect Immun 1996; 64:399-405.
44. Hsieh SM, Hung CC, Chen MY, Sheng WH, Chang SC. Dynamics of plasma cytokine levels in patients with advanced HIV infection and active tuberculosis: implications for early recognition of patients with poor response to anti-tuberculosis treatment. AIDS 1999; 13:935-41.
45. Lawn SD, Rudolph D, Wiktor S, Coulibaly D, Ackah A, Lal RB. Tuberculosis (TB) and HIV infection are independently associated with elevated serum concentrations of tumour necrosis factor receptor type 1 and beta2-microglobulin, respectively. Clin Exp Immunol 2000; 122: 79-84.
46. Toossi Z, Xia L, Wu M, Salvekar A. Transcriptional activation of HIV by Mycobacterium tuberculosis in human monocytes. Clin Exp Immunol 1999; 117:324-30.
47. Toossi Z, Hamilton BD, Phillips MH, Averill LE, Ellner JJ, Salvekar A. Regulation of nuclear factor-kappa B and its inhibitor I kappa B-alpha/MAD-3 in monocytes by Mycobacterium tuberculosis and during human tuberculosis. J Immunol 1997; 159:4109-16.
48. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 1999; 274:28837-40.
49. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res 2000; 28:663-8.
50. Shapiro L, Heidenreich KA, Meintzer MK, Dinarello CA. Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro. Proc Natl Acad Sci USA 1998; 95:7422-6.
51. Cohen PS, Schmidtmayerova H, Dennis J, et al. The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol Med 1997; 3:339-46.
52. Kumar S, Orsini MJ, Lee JC, McDonnell PC, Debouck C, Young PR. Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase. J Biol Chem 1996; 271:30864-9.
53. Valone SE, Rich EA, Wallis RS, Ellner JJ. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobacterial antigens. Infect Immun 1988; 56:3313-5.
54. Wallis RS, Fujiwara H, Ellner JJ. Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. J Immunol 1986; 136:193-6.
55. Naruse K, Ueno M, Satoh T, et al. A YAC contig of the human CC chemokine genes clustered on chromosome 17q11.2. Genomics 1996; 34:236-40.
56. Rollins BJ. Chemokines. Blood 1997; 90:909-28.
57. Vicenzi E, Alfano M, Ghezzi S, et al. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-lalpha, and MCP-3, and enhancement by MCP-1. J Leukoc Biol 2000; 68:405-12.
58. Lim SP, Garzino-Demo A. The human immunodeficiency virus type 1 Tat protein up-regulates the promoter activity of the beta-chemokine monocyte chemoattractant protein 1 in the human astrocytoma cell line U-87 MG: role of SP-1, AP-1, and NF-kappaB consensus sites. J Virol 2000; 74:1632-40.
59. Lin Y, Gong J, Zhang M, Xue W, Barnes PF. Production of monocyte chemoattractant protein 1 in tuberculosis patients. Infect Immun 1998; 66:2319-22.
60. Sadek MI, Sada E, Toossi Z, Schwander SK, Rich EA. Chemokines induced by infection of mononuclear phagocytes with mycobacteria and present in lung alveoli during active pulmonary tuberculosis. Am J Respir Cell Mol Biol 1998; 19:513-21.
61. Mancino G, Placido R, Bach S, et al. Infection of human monocytes with Mycobacterium tuberculosis enhances human immunodeficiency virus type 1 replication and transmission to T cells. J Infect Dis 1997; 175:1531-5.
62. + T cells. Science 1999; 286:1353-7.
63. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998; 19:346-51.
64. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol 2000; 74:139-45.
65. Lawn SD, Butera ST. Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection. J Virol 2000; 74:10256-9.
66. Castilletti C, Capobianchi MR, Fais S, et al. HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells. AIDS Res Hum Retroviruses 1995; 11:547-53.
67. Schwander SK, Sada E, Torres M, et al. T lymphocytic and immature macrophage alveolitis in active pulmonary tuberculosis. J Infect Dis 1996; 173:1267-72.
68. + macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 2001; 184:1127-33.
69. Saifuddin M, Roebuck KA, Chang C, Ting JP, Spear GT. Cutting edge: activation of HIV-1 transcription by the MHC class II transactivator. J Immunol 2000; 164:3941-5.
70. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16:2851-60.
71. Cantin R, Fortin JF, Lamontagne G, Tremblay M. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 1997; 71:1922-30.
72. Juffermans NP, Verbon A, van Deventer SJ, et al. Elevated chemokine concentrations in sera of human immunodeficiency virus (HIV)-seropositive and HIV-seronegative patients with tuberculosis: a possible role for mycobacterial lipoarabinomannan. Infect Immun 1999; 67: 4295-7.
73. Fraziano M, Cappelli G, Santucci M, et al. Expression of CCR5 is increased in human monocyte-derived macrophages and alveolar macrophages in the course of in vivo and in vitro Mycobacterium tuberculosis infection. AIDS Res Hum Retroviruses 1999; 15:869-74.
74. Fantuzzi L, Conti L, Gauzzi MC, et al. Regulation of chemokine/cytokine network during in vitro differentiation and HIV-1 infection of human monocytes: possible importance in the pathogenesis of AIDS. J Leukoc Biol 2000; 68:391-9.
75. Toossi Z, Nicolacakis K, Xia L, Ferrari NA, Rich EA. Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:325-31.
76. Hoshino Y, Nakata K, Hoshino S, et al. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med 2002; 195:495-505.
77. Weiden M, Tanaka N, Qiao Y, et al. Differentiation of monocytes to macrophages switches the Mycobacterium tuberculosis effect on HIV-1 replication from stimulation to inhibition: modulation of interferon response and CCAAT/enhancer binding protein beta expression. J Immunol 2000; 165:2028-39.
78. Tsunetsugu-Yokota Y, Akagawa K, Kimoto H, et al. Monocyte-derived cultured dendritic cells are susceptible to human immunodeficiency virus infection and transmit virus to resting T cells in the process of nominal antigen presentation. J Virol 1995; 69:4544-7.
79. Bernier R, Barbeau B, Olivier M, Tremblay MJ. Mycobacterium tuberculosis mannose-capped lipoarabinomannan can induce NF-kappaB-dependent activation of human immunodeficiency virus type 1 long terminal repeat in T cells. J Gen Virol 1998; 79:1353-61.
80. Lederman MM, Georges DL, Kusner DJ, Mudido P, Giam CZ, Toossi Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. J Acquir Immune Defic Syndr 1994; 7:727-33.
81. Toossi Z, Sierra-Madero JG, Blinkhorn RA, Mettler MA, Rich EA. Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type 1. J Exp Med 1993; 177:1511-6.
82. Honda Y, Rogers L, Nakata K, et al. Type I interferon induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP)beta, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J Exp Med 1998; 188:1255-65.
83. Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med 1999; 190:1679-88.
84. Patten M, Wang W, Aminololama-Shakeri S, Burson M, Long CS. IL-1 beta increases abundance and activity of the negative transcriptional regulator yin yang-1 (YY1) in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2000; 32:1341-52.
85. Coull JJ, Romerio F, Sun JM, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74:6790-9.
86. Vanham G, Penne L, Allemeersch H, et al. Modeling HIV transfer between dendritic cells and T cells: importance of HIV phenotype, dendritic cell-T cell contact and T-cell activation. AIDS 2000; 14:2299-311.
87. Gray CM, Morris L, Murray J, et al. Identification of cell subsets expressing intracytoplasmic cytokines within HIV-1-infected lymph nodes. AIDS 1996; 10:1467-75.
88. Hirsch CS, Toossi Z, Vanham G, et al. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis 1999; 179:945-53.
89. Hirsch CS, Toossi Z, Johnson JL, et al. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis 2001; 183:779-88.
90. Bekker LG, Haslett P, Maartens G, Steyn L, Kaplan G. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 2000; 181: 954-65.
91. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:247-57.
92. Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996; 174:727-33.
93. Wallis RS. A study of safety, immunology, virology, microbiology of adjunctive etanercept in HIV-1-associated TB. AIDS (in press).
94. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995; 171:523-30.